Wayne Koberstein

  1. Companies To Watch: Freya Biosciences 11/1/2023

    Freya Biosciences is enlivening the long-time lonely space of reproductive health, starting with a new focus on the vaginal microbiome.

  2. Rescuing A Company's Core Purpose 10/2/2023

    When Dr. Scott Braunstein moved from his position as chairman of the board and interim CEO to become permanent CEO of Marinus Pharmaceuticals in August 2019, he had already concluded an overbroad focus was holding the company back.

  3. Companies To Watch: Spruce Biosciences 10/2/2023

    Spruce Biosciences is currently in mid-to-late stage clinical development of new agents to treat rare endocrine disorders.

  4. Companies To Watch: Nido Biosciences 9/1/2023

    See why Nido Biosciences is developing small molecule drugs for rare neurodegenerative diseases.

  5. To America, A New Biopharma Model 9/1/2023

    Ketan Mehta, founder and CEO of Tris Pharma. Mehta came to the U.S. in the late 1970s. Since then, he has built a career in pharma and, more recently, an entirely new company with a triad of businesses — platform technology licensing, generic medicines, and new drug development.

  6. Companies To Watch: Ventoux Biosciences 8/1/2023

    Why Ventoux Biosciences is pursuing drug treatments for all sufferers of Dupuytren’s and other fibroproliferative diseases.

  7. Going European — Affimed's American CBO 8/1/2023

    Taking the CBO position at Affimed offered Denise Mueller a way to apply her skills in an international biotech startup environment, where she could help shape the company’s innovative approach to cancer immunotherapy.

  8. Ways To Face New Bio Funding & Banking Risks 7/3/2023

    Funding bio startups has never been easy, but no doubt it just got harder. We wanted to find at least one company to talk about how it is handling the damage and aftermath of recent bank closures and other cash crunches, and we actually found two.

  9. Companies To Watch: Kinaset Therapeutics 7/3/2023

    Kinaset Therapeutics is moving fast in the respiratory space to advance a potential first-time therapy.

  10. A Quick Transition To Late-Stage Clinical Trials 6/1/2023

    “Moving into Phase 3 not only expands the resources you need internally, but some things require a much larger amount of capital, and often a public listing so you can raise larger amounts of money,” says Eric Dobmeier, president and CEO, Chinook Therapeutics.